Doctor vaccinating a woman
© Konstantin Yuganov / stock.adobe.com
In our Blog For the 2020 clinical trials day, we have summarized the COVID-19 studies that have been carried out so far on ISRCTN registration. A year later and it’s over now 170 COVID-19 studies registered. By doing first part From this blog we looked back at the results of the platform Trials and a selection of repurposed drug treatment Attempts that have been started since then. In the second part we look at the results of the vaccine Studies and Studies of Tests and the Effects of COVID-19 on Other Conditions.
Several vaccines for COVID-19 have been developed around the world. The one from the Oxford University and AstraZeneca was tested in Phase I / II, Phase II / III and Phase III Studies and the Results confirmed that the vaccine was effective.
The AstraZeneca vaccine is approved for use in many countries including the UK. Mass vaccination against COVID-19 began in the UK in early December 2020 and is expected to continue through mid-2021. The AstraZeneca vaccine is currently being used in a Phase II study with children.
Other vaccine candidates are being tested in the EU COVAC1, CROWN CROWNING and ENSEMBLE 2 Tries. There are also vaccines under development Valneva and the University of Queensland. The safety of all vaccines is monitored by the VAC4COVID Study first in the UK and by the ZVAC study in Switzerland.
The COV COMPARISON The study compares the immunogenicity of two doses of the vaccines AstraZeneca and Valneva while the Com-COV and Com-COV2 Studies compare different vaccine combinations (e.g. AstraZeneca and Pfizer-BioNTech vaccines) for the Prime and Boost doses, and compare 4-week and 12-week intervals between doses.
The duration of protection of current vaccines is unknown, and additional booster doses may be required in 9 to 12 months, which may coincide with seasonal influenza vaccination. Dispensing COVID-19 and influenza vaccines on separate dates will create significant logistical challenges ComFluCOV The study determines the safety and immune response when both vaccines are given in different arms at the same time.
Testing has been shown to be key to containing the spread of the virus. The Results of CoV-19POC The study showed that a new point-of-care test for COVID-19 produces results faster and can lead to improved measures for infection control and patient flow compared to centralized laboratory PCR tests.
In England and Wales, the infection rate in nursing homes was 80% and the mortality rate was 30-50%. The VIVALDI The study carries out repeat tests (antigen and antibody) of nursing home staff and residents CONTACT A feasibility study is investigating whether wearable digital devices can help improve contact tracking in nursing homes.
The reopening of schools in the UK containing the virus is particularly challenging due to asymptomatic cases, the high number of contacts, the presence of vulnerable people and the possibility of children and staff being passed on to family contacts CoMMinS Study researchers map the COVID-19 infection in participating schools with saliva tests, environmental swabs and wastewater analyzes.
Effects on Other Conditions
The UKOSS The study gathered information on pregnant women hospitalized with COVID-19 in the UK and US Results showed that Most had good results and this transmission to infants was unusual. However, the authors also concluded that the high proportion of women from black or ethnic minorities admitted with an infection urgently needs to be investigated.
Studies also examine the immune responses to COVID-19 and / or vaccinations in patients with chronic health conditions and immunocompromised patients such with cancer and inflammatory bowel disease (IBD) treated with immunosuppressive or biological drugs.
Last year we also published blogs on Heart disease and COVID-19, the Brain complications of COVID-19 and digital self-management for people who live with cancer during the pandemic.
The takeaway message
The ISRCTN registration continues to support global research on COVID-19 by giving priority to the immediate registration and reporting of COVID-19-related studies. All registered studies are made available worldwide by the WHO International platform for the registry of clinical trials (ICTRP) and all UK studies appear on Be part of the research.